These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37778526)

  • 21. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
    Bruderer S; Hurst N; Remenova T; Dingemanse J
    Expert Opin Drug Saf; 2017 Jun; 16(6):743-751. PubMed ID: 28494686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
    Verlinden NJ; Walter C; Raina A; Benza RL
    J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world practice patterns and characteristics of adverse events with selexipag in Korean patients with pulmonary arterial hypertension.
    Chang SA; Lee SH; Choi JH; Chung WJ; Choi JY; Kim HK; Jung HO; Park SM; Kim WJ; Jung SY; Chang HJ
    Expert Opin Drug Saf; 2022 Nov; 21(11):1423-1432. PubMed ID: 35451909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
    Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
    J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
    Beghetti M; Channick RN; Chin KM; Di Scala L; Gaine S; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Rubin LJ; Simonneau G; Sitbon O; Tapson VF; Galiè N
    Eur J Heart Fail; 2019 Mar; 21(3):352-359. PubMed ID: 30632656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early Addition of Selexipag to Double Therapy for Pulmonary Arterial Hypertension.
    Burger CD; Tang W; Tsang Y; Panjabi S
    JAMA Netw Open; 2024 Sep; 7(9):e2434691. PubMed ID: 39312239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report.
    Alexandre A; Furtado I; Carvalho L; Gonçalves F; Melo A; Alves J; Santos M; Reis A
    ESC Heart Fail; 2023 Aug; 10(4):2722-2727. PubMed ID: 37336527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
    Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
    Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
    Rosenkranz S; Channick R; Chin KM; Jenner B; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; McLaughlin VV; Du Roure C; Rubin LJ; Sitbon O; Tapson V; Lang IM
    Eur J Heart Fail; 2022 Jan; 24(1):205-214. PubMed ID: 34806261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacological characteristics and clinical study results of Selexipag (Uptravi
    Kuwano K; Kosugi K; Fuchikami C; Funaki S
    Nihon Yakurigaku Zasshi; 2021; 156(3):178-186. PubMed ID: 33952848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of selexipag for the treatment of pulmonary hypertension.
    Panagiotidou E; Boutou A; Pitsiou G
    Expert Opin Pharmacother; 2021 Jan; 22(1):29-36. PubMed ID: 32867545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Experience with Selexipag to Treat Pulmonary Arterial Hypertension].
    Karelkina EV; Goncharova NS; Simakova MA; Moiseeva OM
    Kardiologiia; 2020 Mar; 60(4):36-42. PubMed ID: 32394855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension.
    Baker WL; Darsaklis K; Singhvi A; Salerno EL
    Ann Pharmacother; 2017 Jun; 51(6):488-495. PubMed ID: 28478717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline history of patients using selexipag for pulmonary arterial hypertension.
    Highland KB; Hull M; Pruett J; Elliott C; Tsang Y; Drake W
    Ther Adv Respir Dis; 2019; 13():1753466619843774. PubMed ID: 30983530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.
    Momoi M; Hiraide T; Shinya Y; Momota H; Fukui S; Kawakami M; Itabashi Y; Fukuda K; Kataoka M
    Ther Adv Respir Dis; 2021; 15():1753466621995048. PubMed ID: 33627044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies.
    Ghosh RK; Ball S; Das A; Bandyopadhyay D; Mondal S; Saha D; Gupta A
    J Clin Pharmacol; 2017 May; 57(5):547-557. PubMed ID: 27670133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selexipag: First Global Approval.
    Scott LJ
    Drugs; 2016 Mar; 76(3):413-8. PubMed ID: 26846322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selexipag for the treatment of pulmonary arterial hypertension.
    Sharma K
    Expert Rev Respir Med; 2016; 10(1):1-3. PubMed ID: 26567613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study.
    Tsang Y; Stokes M; Kim YJ; Tilney R; Panjabi S
    Clin Respir J; 2023 Dec; 17(12):1209-1222. PubMed ID: 37804160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.